利奈唑胺诱导血小板减少症的研究进展

doi:10.12092/j.issn.1009-2501.2018.10.017

摘要/Abstract

摘要：

利奈唑胺（linezolid, LZD）对耐甲氧西林金黄色葡萄球菌、青霉素耐药肺炎球菌和耐万古霉素肠球菌具有良好活性，但血小板毒性大大限制其应用。近年来，利奈唑胺诱导血小板减少症（linezolid-induced thrombocytopenia，LIT）相关研究取得较大进展。LZD被发现与骨髓抑制、抑制巨核细胞释放、氧化应激及免疫破坏等机制密切相关。此外，大量临床研究也总结出LIT的风险因素，并探索出LZD的剂量调整方法，成为LIT防治的突破口。然而不同文献中LIT发病机制、风险因素和LZD剂量调整的差异较大，本文对此开展综述，以期为临床防治LIT提供思路。

关键词: 利奈唑胺, 血小板减少, 风险因素, 剂量调节

Abstract:

Linezolid (LZD) has good antibacterial activity against methicillin-resistant staphylococcus aureus,penicillin-resistant pneumococcus and vancomycin-resistant enterococci. However, platelet toxicity greatly limits its clinical application. In recent years,significant progress has been acheived in studies of the pathogenesis and clinical risk factors of linezolid-induced thrombocytopenia（LIT）. LZD has been found to be closely related to bone marrow suppression, inhibition of platelet release,oxidative stress and immune destruction to result in low platelet count.In addition,a large number of clinical studies had also summarized the risk factors of LIT,and explored the dose adjustment methods of LZD,which became the breakthrough of prevention and treatment for LIT.However,there are many different kinds of opinoins in these literatures.This article reviews the pathogenesis,risk factors,and dose adjustment of LIT,with a view to providing ideas for clinical prevention and treatment of LIT.

Key words: linezolid, thrombocytopenia, risk factors, dose adjustment

中图分类号:

R558+.2

钟玲，邵华，陈燕，胡琳璘，于锋. 利奈唑胺诱导血小板减少症的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(10): 1196-1200.

ZHONG Ling, SHAO Hua, CHEN Yan, HU Linlin, YU Feng. Advance in linezolid-induced thrombocytopenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1196-1200.

参考文献

［1］Dryden MS.Linezolid pharmacokinetics and pharmacodynamics in clinical treatment［J］.J Antimicrob Chemother,2011,66 Suppl 4(Supplement 4):iv7-iv15.
［2］Yuasa A, Sato S, Houzawa H, et al. Postmarketing surveillance of linezolid［J］. Jpn J Chemother, 2017, 65(3): 491-509.
［3］Rabon AD,Fisher JP,MacVane SH,et al.Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater［J］.Ann Pharmacother,2018 Jun 1:1060028018783498.
［4］王东晓，朱曼，郭代红，等. 930例糖肽类和噁唑烷酮类抗感染药物药品不良反应/事件报告分析［J］. 中国药物应用与监测, 2017, 14(1): 37-41.
［5］徐佳，黄琪，杨志玲. 我院区2016年利奈唑胺临床应用合理性评价［J］. 中国临床药理学与治疗学, 2018, 23(1): 110-115.
［6］Li Y, Xu W. Efficacy and safety of linezolid compared with other treatments for skin and soft tissue infections: a meta-analysis ［J］. Biosci Rep, 2018, 38(1): BSR20171125.
［7］Gonzálezdel CJ, Candel FJ, Manzanolorenzo R, et al. Predictive score of haematological toxicity in patients treated with linezolid ［J］. Eur J Clin Microbiol Infect Dis, 2017, 36(8): 1511-1517.
［8］Silva ED, Kim H. Drug-induced thrombocytopenia: Focus on platelet apoptosis ［J］. Chem Biol Interact, 2018, 284: 1-11.
［9］Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients［J］. Antimicrob Agents Chemother, 2011, 55(5): 1867-1873.
［10］Bernstein WB, Trotta RF, Rector JT, et al. Mechanisms for linezolid-induced anemia and thrombocytopenia ［J］. Ann Pharmacother, 2003, 37(4): 517-520.
［11］Pascoalinho D, Vilas MJ, Coelho L, et al. Linezolid-related immune-mediated severe thrombocytopenia［J］. Int J Antimicrob Agents, 2011, 37(1): 88-89.
［12］Chong BH, Chong JH. Drug-induced thrombocytopenia: pathogenesis, diagnosis and management［M］// Platelets in thrombotic and non-thrombotic disorders. Springer International Publishing, 2017:153.
［13］Deng J, Su LX, Liang ZX, et al. Effects of vitamin b6 therapy for sepsis patients with linezolid-associated cytopenias: a retrospective study ［J］. Curr Ther Res Clin Exp, 2013, 74: 26-32.
［14］Flanagan S, Mckee EE, Das D, et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function［J］. Antimicrob Agents Chemother, 2015, 59(1): 178-185.
［15］Milosevic TV, Payen VL, Sonveaux P, et al. Mitochondrial alterations (inhibition of mitochondrial protein expression, oxidative metabolism and ultrastructure) induced by linezolid and tedizolid at clinically-relevant concentrations in cultured human HL-60 promyelocytes and THP-1 monocytes［J］. Antimicrob Agents Chemother, 2018, 62(3): pii: e01599-17.
［16］Nishijo N, Tsuji Y, Matsunaga K, et al. Mechanism underlying linezolid-induced thrombocytopenia in a chronic kidney failure mouse model［J］. J Pharmacol Pharmacother, 2017, 8(1): 8-13.
［17］Tajima M,Kato Y,Matsumoto J,et al.Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2［J］.Biol Pharm Bull,2016,39(11):1846-1851.
［18］Aburima A, Walladbegi K, Wake JD, et al. cGMP signaling inhibits platelet shape change through regulation of the RhoA‐Rho Kinase‐MLC phosphatase signaling pathway［J］. J Thromb Haemost, 2017, 15(8): 1668-1678.
［19］Wang TL, Guo DH, Bai Y, et al. Thrombocytopenia in patients receiving prolonged linezolid may be caused by oxidative stress ［J］. Clin Drug Investig, 2016, 36(1): 67-75.
［20］Araujo CF, Lacerda MV, Abdalla DS, et al. The role of platelet and plasma markers of antioxidant status and oxidative stress in thrombocytopenia among patients with vivax malaria［J］. Mem Inst Oswaldo Cruz, 2008, 103(6): 517-521.
［21］Wang T, Guo D, Dong X, et al. Effect of linezolid on hematological and oxidative parameters in rats ［J］. J Antibiot, 2014, 67(6): 433-437.
［22］Tsuji Y,Holford NHG,Kasai H,et al.Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients［J］.Br J Clin Pharmacol,2017,83(8):1758-1772.
［23］Aster RH, Bougie DW. Drug-induced immune thrombocytopenia ［J］. Am J Hematol, 2015, 68(1): 1-2.
［24］Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience［J］. Antimicrob Agents Chemother, 2002, 46(8): 2723-2726.
［25］Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program ［J］. Clin Infect Dis, 2003, 36(2): 159-168.
［26］Ballesteros MG, Orós MM, Díaz EV, et al. Myelosupression induced by linezolid: a pediatric case［J］. Arch Argent Pediatr, 2017, 115(6): e420-e423.
［27］Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy［J］. J Infect Chemother, 2011, 17(3): 382-387.
［28］Rabon A, Fisher J, Mazur J, et al. Incidence and risk factors for linezolid-associated thrombocytopenia in critically ill patients ［J］. Critical Care Medicine, 2018, 46: 319.
［29］Wu HJ, Wen CH, Jang YT, et al. DI-056 Linezolid induced thrombocytopenia in a patient with renal insufficiency: A case report and a retrospective case study［J］. Eur J Hosp Pharm Sci Pract. 2016, 23(Suppl 1): A142.2-A143.
［30］Hanai Y, Matsuo K, Ogawa M, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia ［J］. J Infect Chemother, 2016, 22(8): 536-542.
［31］Niwa T, Watanabe T, Suzuki A, et al. Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight［J］. Diagn Microbiol Infect Dis, 2014, 79(1): 93-97.
［32］Jia LI, Fan YH, Liao LW, et al. Risk factors for linezolid-associated thrombocytopenia in critically ill adult patients［J］. Chin J Hosp Pharm, 2016.
［33］Niwa T, Suzuki A, Sakakibara S, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy ［J］. Clin Ther, 2009, 31(10): 2126-2133.
［34］Ikuta S, Tanimura K, Yasui C, et al. Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus -infected patients after digestive surgery［J］. J Infect Chemother, 2011, 17(3): 388-391.
［35］Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients［J］. Int J Antimicrob Agents, 2014, 44(3): 242-247.
［36］Ichie T, Suzuki D, Yasui K, et al. The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis ［J］. J Clin Pharm Ther, 2015, 40(3): 279-284.
［37］Zhang YM, Yu W, Zhou N, et al. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid ［J］. Hepatobiliary Pancreat Dis Int, 2015, 14(3): 287-292.
［38］Hiraki Y, Tsuji Y, Hiraike M, et al. Correlation between serum linezolid concentration and the development of thrombocytopenia［J］. Scand J Infect Dis, 2012, 44(1):60-64.
［39］Pea F, Cojutti P, Pagotto A, et al. Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy ［J］. Antimicrob Agents Chemother, 2012, 56(6): 3438-3440.
［40］Kato H, Mao H, Yamagishi Y, et al. Is dose adjustment based on several factors of body size descriptors effective for prevention of thrombocytopenia by linezolid therapy in hemodialysis patients ［J］? Pharmacol Pharm, 2016, 7(10):417-423.
［41］Cojutti P, Pai MP, Pea F. Population pharmacokinetics and dosing considerations for the use of linezolid in overweight and obese adult patients［J］. Clin Pharmacokinet, 2018, 57(8): 989-1000.
［42］Taguchi K,Miyakawa T,Ohmura T,et al.A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency［J］.Scand J Infect Dis,2013,45(1):77-80.

[1]	岳昭蓉, 谢飞, 王欣, 李红玉. 脾多肽注射液对治疗原发性血小板减少症的作用途径研究[J]. 中国临床药理学与治疗学, 2021, 26(11): 1229-1236.
[2]	林忠, 谢群莉, 戴淑萍, 陈静, 林菲阳, 朱燕舞, 余国亮, 张远怀, 崔可. 中国成年患者利奈唑胺治疗群体药动学研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 992-999.
[3]	张乃菊, 陈天平, 黄睿, 陈重, 张帆, 孔令提, 夏娟, 刘金春. 利奈唑胺致乳酸酸中毒研究进展[J]. 中国临床药理学与治疗学, 2020, 25(12): 1408-1413.
[4]	徐佳，黄琪，杨志玲. 我院区2016年利奈唑胺临床应用合理性评价[J]. 中国临床药理学与治疗学, 2018, 23(1): 110-115.
[5]	李春杏, 付强, 朱珠. 利奈唑胺组织穿透性及在感染组织中的药效学[J]. 中国临床药理学与治疗学, 2015, 20(3): 349-355.
[6]	金砚杰, 张晶, 卢克鹏, 刘倩, 林立敏, 宋洪涛. 利奈唑胺的PK/PD与给药方案优化设计研究进展[J]. 中国临床药理学与治疗学, 2014, 19(12): 1429-1434.
[7]	侯瑞英, 伏晓, 代大顺. 利奈唑胺注射液致严重眩晕[J]. 中国临床药理学与治疗学, 2013, 18(11): 1244-1245.
[8]	梁蓓蓓, 王睿, 白楠, 蔡芸. 利奈唑胺、万古霉素对甲氧西林耐药的金黄色葡萄球菌的防耐药突变体选择浓度的研究[J]. 中国临床药理学与治疗学, 2010, 15(3): 251-254.
[9]	梁蓓蓓, 王睿. 利奈唑胺、去甲万古霉素等抗菌药物对耐甲氧西林金黄色葡萄球菌的抗菌活性[J]. 中国临床药理学与治疗学, 2008, 13(9): 1044-1047.
[10]	肖秀美, 刘振英, 张晓伟, 张捷. 利奈唑胺对临床分离阳性球菌的体外敏感性分析[J]. 中国临床药理学与治疗学, 2008, 13(9): 1048-1052.
[11]	袁国龙, 徐亮, 李志, 陈兰芳, 宣丹, 陆进明. 去除IgG的系统性红斑狼疮血小板减少血清对脐带血巨核细胞克隆形成单位生成的影响[J]. 中国临床药理学与治疗学, 2008, 13(10): 1163-1167.
[12]	苏颖杰, 李晶, 姚明辉, 贡沁燕. 重组人血小板生成因子对辐射后C57 小鼠及MO7e 细胞的保护作用[J]. 中国临床药理学与治疗学, 2007, 12(1): 66-71.
[13]	徐国良, 肖兵华, 陈奇, 徐友妹. 阿糖胞苷诱发小鼠血小板减少模型的研究[J]. 中国临床药理学与治疗学, 2005, 10(4): 387-390.